Who are Supemtek®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cabergoline (Dopamine Agonist), placebo with Clozapine, Latuda (Lurasidone), Flupentixole, Haloperidol + lorazepam, Aripiprazole; Quetiapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/supemtek.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Supemtek® — Competitive Intelligence Brief

Supemtek® (Supemtek®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D2 receptor antagonist. Area: Psychiatry.

phase 3 Dopamine D2 receptor antagonist Dopamine D2 receptor Psychiatry Biologic Live · refreshed every 30 min

Target snapshot

Supemtek® (Supemtek®) — Assistance Publique - Hôpitaux de Paris. Supemtek is a small molecule drug that targets the dopamine D2 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Supemtek® TARGET	Supemtek®	Assistance Publique - Hôpitaux de Paris	phase 3	Dopamine D2 receptor antagonist	Dopamine D2 receptor
Cabergoline (Dopamine Agonist)	Cabergoline (Dopamine Agonist)	University Hospital, Basel, Switzerland	marketed	Dopamine agonist	Dopamine D2 receptor
placebo with Clozapine	placebo with Clozapine	Shanghai Mental Health Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Latuda (Lurasidone)	Latuda (Lurasidone)	Massachusetts General Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
Flupentixole	Flupentixole	Technical University of Munich	marketed	Antipsychotic	Dopamine D2 receptors
Haloperidol + lorazepam	Haloperidol + lorazepam	University of Arkansas	marketed	Antipsychotic + benzodiazepine combination	Dopamine D2 receptor (haloperidol); GABA-A receptor (lorazepam)
Aripiprazole; Quetiapine	Aripiprazole; Quetiapine	Taichung Veterans General Hospital	marketed	Atypical antipsychotic combination	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D2 receptor antagonist class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Idorsia Pharmaceuticals Ltd. · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Supemtek® — Competitive Intelligence Brief. https://druglandscape.com/ci/supemtek. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab